Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19

Expanded emergency use authorization includes certain people who have been exposed to someone infected with SARS-CoV-2 or who are at high risk of exposure in an institutional setting INDIANAPOLIS , Sept. 16, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has expanded the